Tub A, a selective HDAC6 antagonist, exhibits low neurotoxicity and multimodal efficiency: it suppresses pro-inflammatory cytokines (TNF-α and IL-6) (56), restores tumor-suppressive primary cilia (57), and inhibits viral RNA synthesis (31). Here, IL6 is linked to neoplasm.